A Phase 3 interventional study of Neoadjuvant chemotherapy in Cervix Cancer, Cervical Cancer and Cancer of the Uterine Cervix, sponsored by Banaras Hindu University. Completed at 1 site in India. Open to female participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2022-05-20.
Sponsored by Banaras Hindu University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Uterine Cervical Neoplasms with a site in India — 17 open to participants now, 21 under way, 3 of them phase 3. Uterine Cervical Neoplasms · India.
Among the 61 studies in Uterine Cervical Neoplasms with a site in India, this one is the 43rd largest by enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2020, is one of 14 in phase 3, and was the 42nd registered.
2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →17 of the 61 studies in Uterine Cervical Neoplasms with a site in India are open now. Recruiting first, the newest first:
Kortuc, Inc. · Sites in India, Thailand, United Kingdom
Ages 18+ · Women only
Tata Memorial Hospital · Sites in India, Japan, Thailand
Women only
University of California, Irvine · Sites in India
Ages 25–50 · Women only
Merck Sharp & Dohme LLC · Sites in India, United States, Argentina and 26 more countries
Ages 18+ · Women only
All India Institute of Medical Sciences · Sites in India
Ages 18–65 · Women only
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 100 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 15 · Phase 4 2
First in 1996; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 100 across 1,740 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 311 across the 44 interventional studies, 800 across the 17 observational. Of the 25 that completed or were terminated, 6 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 61 have an industry lead sponsor. The 10 most frequent:
Banaras Hindu University is the lead sponsor of 21 studies on the registry; 2 are open to participants now.
Banaras Hindu University has 1 study filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
5 of the studies in Uterine Cervical Neoplasms with a site in India that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06079671Phase 3AstraZenecaStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | 2027-11-26 |
| NCT05570422Kortuc, Inc.A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 | 2027-01-30 |
| NCT06644846Tata Memorial HospitalSpatially Fractionated Radiation Treatment for Gynaecological Cancers | 2027-02-28 |
| NCT03386734Centre Hospitalier Universitaire de BesanconInternational Validation Study of Sentinel Node Biopsy in Early Cervical Cancer | 2027-05 |
| NCT07400809Tata Memorial HospitalCervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study. | 2027-06-14 |
Add all 5 to your calendar (.ics) → With an account.
Among the 61 studies in Uterine Cervical Neoplasms with a site in India, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cervical cancer represents the second commonest cancer in women worldwide, with 500,000 new cases and 300,000 deaths reported yearly. Among cervical cancer cases, 80% occur in developing countries and about 70% are identified as advanced cancer. According to the International Federation of Gynecology and Obstetrics (FIGO) staging system, a locally advanced cervical cancer includes stage IB2 to IIB.
Treatment modalities include radical surgery with or without adjuvant radiotherapy (RT), Neoadjuvant Chemotherapy (NAC) plus radical hysterectomy with or without adjuvant RT, and concomitant chemo radiation. Currently, platinum based concurrent chemoradiotherapy is the gold standard for locally advanced cervical carcinoma.
Neoadjuvant chemotherapy has many advantages: decreasing tumor size making surgery easier with improved rate of complete resection, decreased pelvic recurrence rate significantly, decreasing rate of parametrial invasion and lymph node metastasis, better brachytherapy distribution, minimal radiation toxicity, and 15% absolute increase of 5-year survival.
This study will evaluate various factors i.e. patient related (Age, Menopausal status, HPV, HIV, Comorbidities), Tumor related pathological stages (TNM), grade, lymphovascular perineural invasion, lymph nodes, extranodal extension, tumor margins including radial margin, type of tumor i.e. Adeno vs squamous, mutation profile and Treatment related factors (type of NAC, duration of NAC, no of cycles of NAC).
This is a single group prospective study to evaluate factors affecting treatment responses in uterine cervical carcinoma. All patients who will be receiving NAC followed by surgery will be included and assessed for various defined factors influencing response. Responses will be assessed by RECIST 1.1 criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All patients receiving NACT followed by Surgery/RT and willing to give consent will be included in study
Exclusion Criteria:
FIGO Stage Ia/ III/ IV
Patients receiving neoadjuvant paclitaxel 175mg/m2 and carboplatin (AUC5) at three weekly interval by intravenous route
Drug: Neoadjuvant chemotherapy
doublet of taxane and carboplatin
Also known as: Paclitaxel and Carboplatin
Clinical Response
Response to intervention by RACIST criteria 1.1
Time frame: 21 days after completion of third cycles
Pathological response
Pathological response after evaluation of surgical specimen and pathological staging
Time frame: 6 months
Plan to share: Yes — On request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: 6 months
Access criteria: on request
Ran from Aug 2020 to primary completion in Mar 2022, 19 months.
Of 53 non-industry phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 107. This study's 19 months is below that.
Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Banaras Hindu University